We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-14.02%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$270M
AUM Growth
+$46.4M
Cap. Flow
+$86.8M
Cap. Flow %
32.16%
Top 10 Hldgs %
7.48%
Holding
501
New
128
Increased
202
Reduced
102
Closed
67

Sector Composition

Rank Sector Weight
1 Real Estate 18.55%
2 Healthcare 17.07%
3 Materials 11.98%
4 Financials 11.43%
5 Energy 8.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PNT
426
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$102K 0.04%
+15,029
New +$115K
ANAB icon
427
AnaptysBio
ANAB
$1.61B
$101K 0.04%
4,985
+36
+0.7% +$797
GHRS icon
428
GH Research
GHRS
$1.92B
$99K 0.04%
9,952
+3,265
+49% +$42.4K
NUVB icon
429
Nuvation Bio
NUVB
$2.32B
$98K 0.04%
30,234
+14,200
+89% +$61.9K
TIL icon
430
Instil Bio
TIL
$48.2M
$98K 0.04%
1,063
+622
+141% +$88.1K
VTYX
431
DELISTED
Ventyx Biosciences
VTYX
$97K 0.04%
+7,970
New +$119K
ZYME icon
432
Zymeworks
ZYME
$1.71B
$95K 0.04%
17,848
+8,099
+83% +$49K
LONA
433
LeonaBio Inc
LONA
$68.9M
$39K 0.01%
1,291
+135
+12% +$12.4K
ACIU icon
434
AC Immune
ACIU
$233M
-31,014
Closed -$124K
ADAP
435
DELISTED
Adaptimmune Therapeutics
ADAP
-44,300
Closed -$91K
ADCT icon
436
ADC Therapeutics
ADCT
$146M
-19,193
Closed -$282K
AKBA icon
437
Akebia Therapeutics
AKBA
$341M
-65,149
Closed -$47K
ALDX icon
438
Aldeyra Therapeutics
ALDX
$94.7M
-22,945
Closed -$102K
ALGS icon
439
Aligos Therapeutics
ALGS
$25M
-537
Closed -$29K
ALLK
440
DELISTED
Allakos
ALLK
-1,902
Closed -$11K
ANNX icon
441
Annexon
ANNX
$867M
-11,398
Closed -$31K
AUTL
442
Autolus Therapeutics
AUTL
$397M
-27,536
Closed -$115K
BCAB icon
443
BioAtla
BCAB
$5.63M
-150
Closed -$37K
BKLN icon
444
Invesco Senior Loan ETF
BKLN
$6.97B
-6,820
Closed -$148K
BLUE
445
DELISTED
bluebird bio
BLUE
-2,030
Closed -$197K
CGEN icon
446
Compugen
CGEN
$225M
-37,909
Closed -$122K
CNTA
447
DELISTED
Centessa Pharmaceuticals
CNTA
-13,969
Closed -$125K
COGT icon
448
Cogent Biosciences
COGT
$6.95B
-19,452
Closed -$146K
CRIS icon
449
Curis
CRIS
$9.22M
-87
Closed -$83K
CTMX icon
450
CytomX Therapeutics
CTMX
$725M
-25,634
Closed -$68K

Similar funds

Virtus ETF Advisers's Q2 2022 Portfolio in Review

As of Q2 2022, Virtus ETF Advisers held 501 positions worth $270M, up 21% from $223M the previous quarter. Its ten largest holdings account for 7.5% of the portfolio.

Virtus ETF Advisers deployed $86.8M of net new capital in Q2 2022, opening 128 new positions and adding to 202 existing holdings. Its largest new stake was ConocoPhillips: 7,627 shares worth $685K.

By sector, the portfolio is most concentrated in Real Estate at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Materials.

On the sell side, the largest reduction was Agnico Eagle Mines, an estimated $1.83M trimmed.

  • Virtus ETF Advisers's largest Q2 2022 buy was ConocoPhillips: 7,627 shares worth $685K.
  • Virtus ETF Advisers added most to Realty Income in Q2 2022, an estimated $931K increase.
  • Virtus ETF Advisers's biggest Q2 2022 reduction was Agnico Eagle Mines, cutting an estimated $1.83M.
  • Virtus ETF Advisers fully exited BP Midstream Partners LP Common Units representing Limited Partner Interests in Q2 2022, selling an estimated $1.76M.
  • Virtus ETF Advisers's ten largest holdings make up 7.5% of its $270M portfolio in Q2 2022.
  • Virtus ETF Advisers opened 128 new positions and closed 67 in Q2 2022.
  • Virtus ETF Advisers's portfolio value rose 21% quarter-over-quarter to $270M.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.